1. Home
  2. IDR vs DCTH Comparison

IDR vs DCTH Comparison

Compare IDR & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Idaho Strategic Resources Inc.

IDR

Idaho Strategic Resources Inc.

HOLD

Current Price

$31.18

Market Cap

502.0M

ML Signal

HOLD

DCTH

Delcath Systems Inc.

HOLD

Current Price

$16.80

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDR
DCTH
Founded
1996
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
502.0M
578.4M
IPO Year
2000
2015

Fundamental Metrics

Financial Performance
Metric
IDR
DCTH
Price
$31.18
$16.80
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$22.00
AVG Volume (30 Days)
205.7K
673.4K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
70.15
107.53
EPS
0.63
0.04
Revenue
$42,406,253.00
N/A
Revenue This Year
$25.52
$24.54
Revenue Next Year
N/A
$33.15
P/E Ratio
$50.70
$418.25
Revenue Growth
64.59
N/A
52 Week Low
$22.31
$8.12
52 Week High
$54.70
$17.42

Technical Indicators

Market Signals
Indicator
IDR
DCTH
Relative Strength Index (RSI) 46.98 69.91
Support Level $27.46 $10.16
Resistance Level $41.05 N/A
Average True Range (ATR) 1.82 0.79
MACD 0.23 0.37
Stochastic Oscillator 41.09 88.85

Price Performance

Historical Comparison
IDR
DCTH

About IDR Idaho Strategic Resources Inc.

Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: